



# Research **Tumour Biology**

ReTuBi

Towards outstanding research  
and training in tumour biology

**MM**  
Lisboa

institut **Curie**

**dkfz.**  
GERMAN  
CANCER RESEARCH CENTER  
IN THE HELMHOLTZ ASSOCIATION



*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 692322*

## What is the ReTuBi project?

Cancer is a major public health issue and there is an urgent need to find more efficient therapies with decreased side effects.

Through the ReTuBi project a network of excellence, including IMM in Portugal, Institut Curie in France and DKFZ in Germany, will contribute to outstanding pre-clinical research in tumour biology. The consortium will support scientific and technological exchanges and aims ultimately to promote translational research into the benefits of cancer patients.

The overall goal is to strengthen IMM, the coordinating institution, through the establishment of a network of interactions between the involved groups.

## Objectives

- Improve the quality and impact of pre-clinical research in tumour biology at IMM
- Implement and develop novel technology at IMM, Institut Curie and DKFZ crucial to tackle current and future challenges in tumour biology
- Stimulate a long-term impact in innovation at IMM, Institut Curie and DKFZ by fostering research excellence and technological development
- Enhance IMM researchers' ability to integrate networks of excellence within Europe
- Promote awareness of the societal impact of IMM's research in the cancer field, with special focus in oncological patients and respective families as well as the medical community at the Lisbon Academic Medical Centre

## Main activities

- Staff exchanges
- Workshops
- Experts visits
- Summer schools
- Consortium meetings
- Dissemination and outreach

## Who is involved in the consortium?

### iMM / Instituto de Medicina Molecular – Portugal

The IMM is a Portuguese private non-profit research institute that aims to nurture innovative ideas in basic, clinical and translational biomedical research. Created in 2002, with the mission to improve human health through the study of disease mechanisms and the development of novel diagnostic tests and therapeutic approaches, IMM comprises the Lisbon Academic Medical Centre together with Santa Maria Hospital and the Lisbon Medical School of University of Lisbon.

### Institut Curie – France

The Institut Curie is a private non-profit organization created in 1909, on a model devised by Marie Curie and still at the cutting edge: "from fundamental research to innovative treatments". Institut Curie is a cancer foundation and comprises of a research centre and a hospital dedicated entirely to the care of cancer patients. It is the largest European oncology research centre.

### DKFZ / Deutsches Krebsforschungszentrum – Germany

The DKFZ (German Cancer Research Centre) is the largest biomedical research institute in Germany. The strategic goals of DKFZ are to contribute towards a better understanding of fundamental processes in cancer and to develop innovative methods of cancer diagnostics and therapy. Established in 1964, the DKFZ investigates how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic.

### ReTuBi in a Nutshell

**Project title:** Towards outstanding research and training in tumour biology at IMM

**Project acronym:** ReTuBi

**Project reference:** 692322

**Project coordinator:** Edgar Gomes (iMM)

**Funding scheme:** H2020-TWINN-2015 (Spreading Excellence and Widening Participation - Twinning)

**Total investment:** EUR 999 975

**Start date:** 01 January 2016

**End date:** 31 December 2018

**Consortium:** IMM - Portugal, Curie - France, DKFZ - Germany

Twinning is an action from “Spreading Excellence and Widening Participation” - Horizon 2020 programme and its main aim is to address networking gaps and deficiencies between research institutions of the low performing Member States and internationally-leading counterparts at EU level.

### Do you want to know more?

#### Contact us:

Instituto de Medicina Molecular  
Faculdade de Medicina da Universidade de Lisboa  
Av. Professor Egas Moniz; 1649-028 Lisboa - Portugal

Email: [imm-tumourbiology@medicina.ulisboa.pt](mailto:imm-tumourbiology@medicina.ulisboa.pt)

[www.tumourbiology.eu](http://www.tumourbiology.eu)



*This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 692322*